Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin as Adjunct Therapy in Proteinuric Type 2 Diabetic Patients
NCT06425705Phase 2Completed
- Sponsor
- Lahore General Hospital
- Start
- Feb 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in diabetic nephropathy (DN) comparing Group Silymarin with Group Placebo (2 arms). Primary endpoints: Urinary Albumin-Creatinine Ratio at 3 months, Estimated Glomerular Filtration Rate at 3 months and 1 more. Started Feb 2022; status: completed.
02
Drugs
silymarin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06425705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06425705.